Filing Details

Accession Number:
0001181431-13-047080
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2013-08-30 16:29:24
Reporting Period:
2013-08-27
Filing Date:
2013-08-30
Accepted Time:
2013-08-30 16:29:24
Original Submission Date:
2013-08-29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1311596 Regado Biosciences Inc RGDO Pharmaceutical Preparations (2834) 030422069
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1579466 Rusnanomedinvest Llc Business-Center 29/22
Capital Tower 1-St Brestskaya Street
Moscow 1Z 125047
No No Yes No
1579787 S.a.r.l. Investments Rmi Business-Center 29/22
Capital Tower 1-St Brestskaya Street
Moscow 1Z 125047
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Per Share Acquisiton 2013-08-27 1,369,988 $0.00 1,369,988 No 4 C Direct
Common Stock, Par Value $0.001 Per Share Acquisiton 2013-08-27 3,866,529 $4.00 5,236,517 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock, Par Value $0.001 Per Share Series E Preferred Stock Disposition 2013-08-27 22,878,805 $0.00 1,369,988 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
Footnotes
  1. The reportable securities are directly held by the Reporting Person. The Reporting Person is a wholly-owned subsidiary of RusnanoMedInvest LLC ("RMI LLC"). RMI LLC has voting and dispositive power over the shares held by the Reporting Person.
  2. The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.